| Literature DB >> 20299957 |
Matthijs van Luin1, Marchina E Van der Ende, Clemens Richter, Mirjam Visser, Diari Faraj, Andre Van der Ven, Luc Gelinck, Frank Kroon, Ferdinand W Wit, Ron H N Van Schaik, Paul F M Kuks, David M Burger.
Abstract
HIV-infected travellers frequently use atovaquone/proguanil as malaria prophylaxis. We compared atovaquone/proguanil pharmacokinetics between healthy volunteers and HIV-infected patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. The geometric mean ratio (95% confidence interval) area under the curve (AUC)0-->t for atovaquone relative to the healthy volunteers was 0.25 (0.16-0.38), 0.26 (0.17-0.41) and 0.54 (0.35-0.83) for patients on efavirenz, lopinavir/ritonavir and atazanavir/ritonavir, respectively. Proguanil plasma concentrations were also significantly lower (38-43%). Physicians should be alert for atovaquone/proguanil prophylaxis failures in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20299957 DOI： 10.1097/QAD.0b013e3283389129
Source DB: PubMed Journal: AIDS ISSN： 0269-9370 Impact factor: 4.177